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1. Natural history model of disease recurrence 
The structure of the natural history model is depicted in Figure A1. The natural history model 
simulates the development of recurrent cervical intraepithelial neoplasia (CIN) and invasive cervical 
cancer in cohorts of women treated for CIN. The natural history model component for CIN and 
cervical cancer development in women previously treated for CIN was adapted from the post-
treatment recurrence component of a previously published population-based model which included 
components for CIN natural history, cervical screening, post-treatment recurrence and invasive cancer 
survival.1 After incorporating screening, management and compliance appropriate to the setting, this 
larger model has been previously calibrated to the age-specific prevalence of oncogenic HPV in 
cytologically-normal women, observed rates of histologically confirmed high-grade lesions, and 
cervical cancer age-specific incidence and mortality rates.2-4 The age-standardised annual progression 
rate from CIN3 to asymptomatic localised cancer was calibrated to be 1.3%, consistent with the 
available data.5  
 
Women successfully treated for CIN were assumed to be histologically negative after treatment 
(although treatment failure at 3.7% was also included in the model). The model assumed 16% of 
successfully treated women remained infected with HPV (see Table A1). This proportion was 
obtained from a systematic review of the relevant literature2 3 and was assumed to be the same in 
women treated for low-grade and high-grade CIN. Women treated for CIN1 were assumed to be at a 
post-treatment risk for new infections and to follow a natural history for HPV and CIN consistent with 
the general at-risk female population.  Women treated for histologically-confirmed CIN2/3 were 
assumed to be at an increased risk for recurrent CIN2+, with the risk in this group dependent on post-
treatment HPV status. The rate of disease recurrence was obtained via systematic review of recurrence 
rates and of the relative risk of recurrence in HPV-positive versus HPV-negative women after 
treatment.2 3 
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The parameters used by the model in the simulation of the natural history of CIN after treatment for 
CIN1, for disease recurrence after treatment for CIN2/3, and for the natural history of invasive 
cervical cancer, are summarised in Table A1.  
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Figure A1. Schematic of the model of recurrent CIN and invasive cervical cancer* 
 
CIN: Cervical intraepithelial neoplasia; HPV: Human papillomavirus 
 
*
 In each cycle, an age-specific rate of having benign hysterectomy and death from causes other than cervical 
cancer are also applied.  
† The probability of recurrent disease is dependent on whether HPV infection is potentially detectable at 6 
months post-treatment, irrespective of whether or not the post-treatment strategy under evaluation actually 
includes HPV testing at 6 months.  
‡
 In each cycle, patients diagnosed with invasive cervical cancer experience an additional stage-specific rate of 
cervical cancer mortality and an age-specific rate of death from causes other than cervical cancer. Patients 
who survive 5 years are considered cancer survivors. 
 
  
Treated for 
CIN1*
No HPV detectable at 6 
months †
HPV detectable at 6 
months †
CIN1
CIN2
CIN3
Asymptomatic 
localised cancer
Asymptomatic 
regional cancer
Symptomatic 
localised cancer ‡
Symptomatic 
regional cancer ‡
Symptomatic distant 
metastases ‡
Asymptomatic 
distant metastases
No HPV detectable at 6 
months †
HPV detectable at 6 
months †
CIN2
CIN3
Treated for 
CIN2/3*
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Table A1 - Parameters used by the model for the natural history of recurrent CIN and invasive 
cervical cancer 
Parameter Value* 
Annual progression and regression rates in the women who were successfully treated for 
CIN1† § 
Incidence of new oncogenic HPV infections 
30-34 years 0.0732  
35-39 years 0.0592  
40-44 years 0.0553  
45-49 years 0.0379  
50-54 years 0.0378  
55-59 years 0.0273  
60-64 years 0.0192  
65-69 years 0.0175  
70-74 years 0.0175  
Clearance of HPV infection 
30-39 years 0.5500 
40-44 years 0.5000 
45-49 years 0.4500 
50-54 years 0.4000 
55-59 years 0.3500 
60-74 years 0.3000 
HPV to CIN1 
30-44 years 0.0900 
45-74 years 0.0700 
HPV to CIN2 
30-34 years 0.0200 
35-44 years 0.0100 
45-74 years 0.0050 
CIN1 to Uninfected 0.2300 
CIN1 to HPV 0.0300 
CIN1 to CIN2 
30-44 years 0.0300 
45-74 years 0.0400 
CIN1 to CIN3 
25-39 years 0.0300 
40-74 years 0.3310 
CIN2 to Uninfected 0.3150 
CIN2 to HPV 0.0350 
CIN2 to CIN1 0.1215 
CIN2 to CIN3 
30-34 years 0.1500 
35-44 years 0.1800 
45-54 years 0.2000 
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Parameter Value* 
55-64 years 0.2200 
65-74 years 0.2400 
CIN3 to CIN1 
30-34 years 0.0700 
35-59 years 0.0300 
60-74 years 0.0100 
CIN3 to CIN2 
30-39 years 0.0500 
40-49 years 0.0200 
50-59 years 0.0150 
60-74 years 0.0100 
CIN3 to asymptomatic localised cancer 
30-34 years 0.0100 
35-39 years 0.0175 
40-44 years 0.0225 
45-49 years 0.0250 
50-54 years 0.0300 
55-64 years 0.0350 
65-74 years 0.0400 
Health status after successful treatment for CIN|| 
HPV detectable at 6 months 0.1580 
No HPV detectable at 6 months 0.8420 
Annual rate of recurrent disease after successful treatment for CIN2/3 
No HPV detectable to CIN2|| 0.0015 
No HPV detectable to CIN3|| 0.0033 
HPV to CIN2|| 0.0527 
HPV to CIN3|| 0.1115 
CIN2 to CIN3 
Same rate as for women successfully 
treated for CIN1  
CIN3 to CIN2 
Same rate as for women successfully 
treated for CIN1 
CIN3 to non-symptomatic localised cancer 
Same rate as for women successfully 
treated for CIN1 
Annual progression rate of non-symptomatic invasive cervical cancer  
Localised to regional spread 
30-49 years 0.0592 
50-59 years 0.1316 
60-69 years 0.2925 
70-74 years 0.6500 
Regional cancer to distant metastases 0.0450 
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Parameter Value* 
Annual symptomatic detection rate of invasive cervical cancer‡ 
Localised cancer 0.1500 
Regional cancer 0.3000 
  Distant cancer 0.9000 
 
CIN: Cervical intraepithelial neoplasia; HPV: Infected with human papillomavirus but without cervical 
intraepithelial neoplasia;  
*
 Because the time step used in the model was 6 months, the parameters applied were the equivalent 6-monthly 
rate, which were converted from the values presented after taking into account competing risks in each 
transition. 
† Parameters for transitions in women aged 30-74 years only are presented, as these were the only parameters 
applied in this study (determined by the age range of the simulated cohorts and the length of the simulation).  
‡
 Parameters from a previously calibrated and validated model. 1-4  
§
 Parameter values are equivalent to those for the general at-risk female population. 
|| Parameters obtained from a systematic review of the international literature.2 3 
 
 
In each cycle, an age-specific rate of death from causes other than cervical cancer was applied for 
women in all health states and an age-specific rate of benign hysterectomy was applied to women 
without detected cervical cancer cancer. The rate of death from causes other than cervical cancer was 
calculated using data for all-cause mortality6 after subtracting the appropriate cervical cancer 
mortality rate.7. The age-specific hysterectomy rate was obtained from a prior study.8  
 
 
2. Configuration of modelled cohort 
In the primary analysis, we assumed an age and disease distribution among treated women consistent 
with that observed at the HPV Sentinel Sites9 (data obtained via personal communication, Rachel 
Kelly, Institute of Cancer Research, London). Age was included in the model because many factors 
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were age-dependent, including screening recommendations and aspects of management, screening 
compliance, other cause mortality, probability of benign hysterectomy or unsatisfactory colposcopy, 
and natural history parameters. The grade of CIN for which women were initially treated was 
included in the model, because the original guidelines prescribed differential follow-up for women 
treated for CIN1 to that for women treated for CIN2/3.10 
 
Women included in the HPV Sentinel Sites evaluation were aged 25-64 years and otherwise met 
eligibility criteria for cervical cancer screening. Some of the HPV Sentinel Sites used HPV triage in 
the management pathway leading to initial treatment, and some used NHS guidelines which were 
current at that time (that is, women were referred to colposcopy on the basis of cytology results only; 
HPV triage was not performed in the management of borderline or mild cytology results). Because the 
population seen at colposcopy and then subsequently treated may differ in terms of distributions of 
age and grade of disease when referral protocols differ, for sensitivity analysis we constructed 
alternative, theoretical, treated populations, with differing age and/or incoming CIN grade 
distributions. The source of data for each theoretical alternate population is summarised in Table A2; 
in addition to data from the Sentinel Sites, we also used information from a cohort of women treated 
for CIN in London, Manchester, and Aberdeen, described in Kitchener et al (2008).11 Alternate 
Population 1 has an age distribution consistent with the Kitchener study cohort (in which 73% of the 
treated population were aged less than 35 years), whilst the CIN distribution remains consistent with 
that seen at the HPV Sentinel Sites.  Alternate Population 2 has a distribution of CIN1 vs. CIN2/3 
consistent with the Kitchener study cohort (in which 24% were treated for CIN1, and 76% for 
CIN2/3), but an age distribution consistent with the HPV Sentinel Sites. Alternate Population 3 is 
consistent with the Kitchener study cohort both in terms of age and grade of CIN distribution at 
baseline. The various parameter value combinations are shown Table A3 (values in bold are used in 
the primary analysis; values in square brackets refer to Alternative Populations 1-3 as described 
above). 
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Table A2. Data sources and assumptions used for age and disease characteristics of 
theoretical model populations of treated women 
Population Age distribution of 
population 
Disease distribution at 
the time of treatment 
 
Primary analysis 
population 
HPV Sentinel Sites HPV Sentinel Sites  
Alternative Population 1* Kitchener (BJOG 2008) HPV Sentinel sites  
Alternative Population 2* HPV Sentinel Sites Kitchener (BJOG 2008)  
Alternative Population 3* Kitchener (BJOG 2008) Kitchener (BJOG 2008)  
*Populations used for sensitivity analysis. 
 
Table A3. Characteristics of the modelled treated cohort: Distribution of age and grade of 
CIN at the time of initial treatment 
Starting age 
(years) 
Proportion by CIN grade within each age group (%) 
[value sets used in sensitivity analysis] 
Proportion of 
population in age 
group (%) 
[value sets used in 
sensitivity analysis] 
 CIN1 CIN2 CIN3+ 
30 
(midpoint 
representing 
a cohort 25 – 
34 years) 
7 
[8, 20, 21] 
33 
[32,37,37] 
60 
[60, 43, 42] 
63 
[73, 63, 73] 
42 
(midpoint 
representing 
a cohort 35 – 
49 years) 
13 
[12, 29, 30] 
31 
[31,35,34] 
56 
[57, 36, 36] 
35 
[25,35, 25] 
57 
(midpoint 
representing 
a cohort 50 – 
64 years) 
40 
[41, 41, 40] 
21 
[21,29,30] 
39 
[38, 30, 30] 
2 
[2, 2, 2] 
% of total 
treated 
10 
[9.7, 23.6, 23.6] 
32 
[31.8, 36.1, 36.1] 
58 
[58.6, 40.3, 40.3] 
100 
Baseline values used for the primary analysis are shown in bold and values in square brackets refer to 
Alternative Populations 1-3. Some values adjusted so that totals add to 100% for each population.  
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3. Compliance assumptions 
3.1 Assumed compliance with colposcopy attendance and follow-up after 
treatment 
In the primary analysis, compliance rates for attending colposcopy were based on 2007-2008 statistics 
from the Cervical Screening Programme in England.12 Compliance rates for follow-up after treatment 
were based on a study of women treated for CIN.11 Table A4 summarises the assumed compliance 
with follow-up and the range used in sensitivity analysis. 
 
We also considered a scenario where there was perfect compliance with all management 
recommendations (best case scenario). Women who did not attend for a follow-up visit were assumed 
to have the same probability of attending for a routine smear as the general population, unless they 
were symptomatic and thus re-attended earlier.  
Table A4 - Compliance with follow-up after treatment 
Parameter Base case value Range for sensitivity 
analysis 
Compliance with colposcopy recommendation* 
 
84% 12   84% – 100%† 
Compliance at 6 month follow-up visit 
 
100% - 
Compliance at 12 month visit (among those who 
attended at 6 months) 
 
85% 11 85  - 100%† 
Compliance at 24 month visit (among those who 
attended at 12 months) 
 
83% 11 83  - 100%† 
Compliance with (re-)treatment 100% - 
* Based on observed “did not attend” (DNA) rates for follow-up colposcopies.12     
†
 The high end of this range (100%) is an assumption, set to encompass the possibility of perfect compliance 
with colposcopy recommendations. 
 
 
3.2. Assumed compliance for women discharged back to routine screening 
We assumed that women who had been treated and then returned to routine screening would have 
similar compliance with routine screening recommendations as women in the general population. We 
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used registry data from Oxfordshire to estimate the cumulative re-screened proportion at various times 
after a negative smear for women who appeared on the register.13 From this, and age-specific 
coverage data,12 we derived an age- and interval-specific probability of a woman attending for routine 
screening, as previously described.4 This allowed us to include the impact of some early and late re-
screening. Because the data were derived from a region and at a time where three-yearly screening 
was recommended for all ages, we only applied these re-screening probabilities to women with a 
recommended screening interval of three years (ages 25-49 years). For women with a recommended 
screening interval of five years (ages 50-64 years), we assumed there would be no early or late re-
screening, but that all women would re-attend every 5 years.   
4.  Management pathways 
The model of post-treatment follow-up was constructed to incorporate management pathways for 
three alternative strategies (cytological only follow-up, Sentinel Site Protocol and the Extended HPV 
Follow-up Protocol). The model also included pathways to simulate management after colposcopy 
referral in previously treated women, as well as pathways of screening and colposcopy management 
for women who are returned to routine screening. 
 
4.1 Management according to cytological only follow-up  
The post-treatment management pathway is depicted in Figure A2. This was constructed according to 
the recommendations in Sections 9.2, 9.3 and 9.4 of the Colposcopy and Programme Management 
guidelines of the NHS Cancer Screening Programmes (2004).10 Expert opinion was obtained for 
management details that were not directly specified in this guideline (Prof. Henry Kitchener, 
University of Manchester, personal communication).  
 
In the model, women treated for CIN were followed-up with a cytology test at 6 months after 
treatment. At this follow-up visit, women with a borderline dyskaryosis or worse cytology result 
underwent colposcopy examination and were re-treated, and women with a negative cytology result 
were followed-up with annual cytology starting from 12 months post-treatment until testing negative 
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on either two consecutive annual follow-up visits (if treated for low-grade CIN), or ten consecutive 
visits (if treated for high-grade CIN), before returning to screening at the routine interval. Women 
with borderline dyskaryosis or worse cytology at any of the follow-up visits were referred to 
colposcopy and managed according to both colposcopy and cytology findings (further details of 
colposcopy management for women under post-treatment follow-up are given in Section 5.4). 
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Figure A2. Management according to cytological only follow-up 
 
CIN 1: Histologically-confirmed cervical intraepithelial neoplasia; CIN2/3: Histologically-confirmed cervical 
intraepithelial neoplasia; 
 
*Assumes all women with a cytological abnormality at 6 months will undergo colposcopy and receive re-
treatment. 
 
 
4.2. Management according to the Sentinel Site Protocol 
The post-treatment management pathway constructed to simulate the Sentinel Site Protocol is 
depicted in Figure A3. This was constructed according to management specified at the Sentinel Sites,9 
and expert opinion was sought to informed details of the management that were not specified in the 
study protocol (Prof. Henry Kitchener, University of Manchester, personal communication). Under 
this protocol, women treated for CIN were followed-up with both cytology and HPV testing at 6 
months after treatment. Women with borderline dyskaryosis or worse cytology or who were HPV 
positive underwent colposcopy and were re-treated; women testing negative with both tests were 
returned to routine screening (see Section 5.6). Re-treated women were followed-up with another 
Borderline 
dyskaryosis 
or worse
Negative
Moderate 
dyskaryosis or 
worse
Negative
6-months post-
treatment 
management: 
cytology test
Colposcopy evaluation and treatment.*
Post-treatment follow-up as per ‘6-
months post-treatment management’ 
described in this figure
Colposcopy evaluation. The following 
management is described in Figure A6
Repeat cytology test in 12 months . The 
following management as per ‘12-months 
post-treatment management’ described in 
this figure. Women treated for CIN 2/3 being 
tested negative consecutively by cytology for 
10 years can return to routine screening 
management described in Figure A7; women 
treated  for CIN 1 can return to routine 
screening management after  two consecutive 
negative cytology tests
Borderline/ mild 
dyskaryosis Colposcopy evaluation. The following 
management is described in Figure A5
12-months post-
treatment 
management: 
cytology test
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cytology and HPV test at 6-months and if negative by both tests, they received annual cytology testing 
thereafter. 
Figure A3. Management according to the Sentinel Site Protocol 
  
*Assumes all women with a cytology abnormality at 6 months will undergo colposcopy and receive re-
treatment. 
 
 
4.3 Management according to the Extended HPV Follow-up Protocol 
The post-treatment management pathway constructed to simulate the Extended HPV Follow-up 
Protocol is depicted in Figure A4. This was constructed according the strategy evaluated by Kitchener 
et. al.11  and expert opinion was sought to informed details of the management that were not specified 
in the study protocol (Prof. Henry Kitchener, University of Manchester, personal communication).  
Under this protocol, women treated for CIN were followed-up with both cytology and HPV testing at 
6 months. Women with a borderline dyskaryosis or worse cytology or who were HPV positive 
underwent colposcopy and re-treatment; women testing negative were screened at 12 months with 
Borderline 
dyskaryosis 
or worse
Cyto 
negative but 
HPV postive
Exit post-treatment management and 
return to routine screening management 
described in Figure A7
Both tests 
negative
6-months post-
treatment 
management : 
cytology and HPV 
testing
Colposcopy evaluation and treatment. *
Post-treatment follow-up  as per ‘6-
months post-treatment management’ 
described in this figure
Colposcopy evaluation and treatment. *
Post-treatment follow-up as per ‘6-
months post-treatment management’ 
described in this figure
Repeat cytology test in 12 months. The 
following management as per ‘12-months 
post-treatment management’ described in 
Figure A2
Women tested negative 
by both test after the 
initial treatment result
Women who underwent 
additional treatment due 
to  tested positive by one 
or more more tests at 
post-treatment follow-up 
after the initial treatment
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both cytology and HPV testing and at 24 months with cytology alone. Women with a borderline 
dyskaryosis or worse cytology or who were HPV positive during the follow-up visits at 12 or 24 
months post-treatment were referred to colposcopy and managed according to the colposcopy and 
cytology findings (see Section 5.4 for further details of colposcopy management). Women negative by 
cytology at 24 months post-treatment were returned to screening at the routine interval if they had 
been both cytology and HPV negative at 6 and 12 months after the initial treatment, but women who 
had previously had a one or both positive test results at either the 6 and 12 month visits continued 
annual cytology testing (described in Section 5.1).  
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Figure A4. Management according to the Extended HPV Follow-up Protocol 
 
Borderline 
dyskaryosis 
or worse or 
HPV positive
Both tests 
negative
Both tests 
negative
6-months post-
treatment 
management : 
cytology and 
HPV testing
12-months 
post-treatment 
management : 
cytology and 
HPV testing
Colposcopy evaluation and treatment.*
Post-treatment follow-up as per ‘6-
months post-treatment management’ 
described in this figure
24-months 
post-treatment 
management : 
cytology  test
Borderline 
dyskaryosis 
or worse
Women consecutively testing negative 
by both cytology @ 6, 12 and 24 
months and HPV testing @ 6 and 12 
months after initial treatment will 
return to routine screening 
management (see Figure A7). Treated 
women who were again referred to 
colposcopy (with or without re-
treatment) will have repeat cytology 
testing at 12 months. Subsequent 
management of these women is as per 
the ‘12-months post-treatment 
management’ described in Figure A2. 
Colposcopy evaluation. See Figure A6  for 
colposcopy management for cytology 
moderate dyskaryosis or worse. 
Management for all other less severe 
cytology result is described in Figure A5 
Negative
Colposcopy evaluation. See Figure A6  for 
colposcopy management for cytology 
moderate dyskaryosis or worse. 
Management for all other less severe 
cytology result is described in Figure A5 
Borderline 
dyskaryosis 
or worse or 
HPV positive
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*Assumes all women with a cytology abnormality at 6 months will undergo colposcopy and receive re-treatment. 
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4.4 Post-colposcopy management for women undergoing post-treatment follow-
up  
The post-colposcopy management pathway for women referred with borderline/mild cytology when 
they are undergoing post-treatment follow-up is depicted in Figure A5. This pathway was constructed 
according to the recommendations in Section 9 of the 2004 NHS guidelines.10 Expert opinion was 
sought for detailed aspects of management not directly specified in the guidelines (Prof. Henry 
Kitchener, University of Manchester, personal communication).  
 
Women referred to colposcopy after a borderline or mild dyskaryosis cytology result, for whom 
colposcopy was satisfactory and normal, were followed-up at 6 months and then managed according 
to the applicable post-treatment management protocol. Women with a satisfactory but abnormal 
colposcopy result had a punch biopsy. Women diagnosed with invasive cervical cancer were referred 
to cancer treatment, women with histologically-confirmed CIN were treated and followed up at 6 
months and were thereafter managed according to the applicable post-treatment management 
protocol, and women with negative histology were followed up at 6 months. Women with 
unsatisfactory colposcopy were followed up at 6 months (Figure A5). 
 
The post-colposcopy management pathway for women referred with moderate/severe cytology when 
they are undergoing post-treatment follow-up is depicted in Figure A6. Women with a satisfactory but 
abnormal colposcopy received punch biopsy. Women with unsatisfactory colposcopy and women 
with satisfactory but normal colposcopy result were assumed to receive cone biopsy. 
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Figure A5. Post-colposcopy management for women post-treatment, who are referred to colposcopy after a borderline or mild cytology result  
 
CIN: Histologically-confirmed cervical intraepithelial neoplasia 
*Depending on which management protocol is being modelled; see Figure A2 for cytological only follow-up; A3 for the HPV Sentinel Sites protocol; A4 for 
the Extended HPV Follow-up Protocol) 
Satisfactory 
result
Unsatisfactory 
result
Abnormal
Cancer
Histologically-
confirmed CIN
Negative
Normal
Age > = 50 years
Age < 50 years
Colposcopy
Punch Biopsy
Under current 
practice or Sentinel 
Site protocol
Under extended 
HPV follow-up 
Protocol
Under the 12-months post-
treatment management
Cancer treatment
Treatment for CIN. The following 
management is described as ‘6-months post-
treatment management’ in Figure A2-A4*
Managed as per women with satisfactory and 
normal colposcopy result described in this 
figure
Cancer
Histologically-
confirmed CIN
Negative Managed as per women with satisfactory 
and normal colposcopy result described in 
this figure
Cancer treatment
Post-treatment follow-up in 6 months is 
described as ‘6-months post-treatment 
management’ in Figure A2-A4*
Managed as per women with 
satisfactory and normal colposcopy 
result described in this figure
Cone Biopsy
Repeat cytology test in 6 months. The 
following management as per 12-months 
post-treatment management’ described in 
Figure A2
Under the 24-months post-
treatment management
Repeat cytology and HPV test in 6 months. 
The following management as per ‘12-
months post-treatment management’ 
described in this Figure A4
Repeat cytology test in 6 months. The 
following management as per 12-months 
post-treatment management’ described in 
Figure A2
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Figure A6. Post-colposcopy management for women post-treatment, who are referred to 
colposcopy with a moderate or severe dyskaryosis cytology result 
 
 
 
4.5. Routine screening management 
The model structure for management after routine screening is depicted in Figure A7. The model was 
constructed according to the recommendations of the 2004 NHS guideline.10 Women were referred for 
colposcopy evaluation if the cytology result showed borderline dyskaryosis or worse. Women with a 
negative cytology result had a repeat cytology test in 3 years if they were aged 25-49 years or in 5 
years if they were aged 50-64 years. 
Satisfactory 
result
Unsatisfactory 
result
Abnormal
Normal
Colposcopy
Cone biopsy. The following 
management as per management of 
cone biopsy management described in 
Figure A5
Punch biopsy. The following 
management as per management of 
punch biopsy described in Figure A5
Cone biopsy. The following 
management as per management of 
cone biopsy management described in 
Figure A5
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Figure A7.  Management following routine screening 
 
 
4.6 Follow-up management for women referred to colposcopy, found to harbour 
confirmed CIN 1 and not treated 
The management pathways for women referred to colposcopy and then found to have a low grade 
abnormality that was not treated are depicted in Figure A8. The model was constructed according to 
the recommendations of the 2004 NHS guidelines.10 Women were followed up with cytology at 6 
months; women with a negative result were returned to routine screening, and women with mild 
dyskaryosis or worse were referred to colposcopy. If cytology was borderline dyskaryosis they were 
referred to colposcopy if they had a recent (12 month) history of moderate dyskaryosis or worse, or 
otherwise were followed up with cytology in 12 months.  Women were followed up annually with 
cytology and were returned to screening at the routine interval after testing negative on two 
consecutive annual follow-up visits; women with borderline dyskaryosis or worse cytology were 
referred to colposcopy and managed according to both colposcopy and cytology findings (further 
details of colposcopy management are given in Section 5.7). 
 
  
Moderate 
dyskaryosis or 
worse
Negative
Routine 
screening 
management: 
cytology test
Colposcopy evaluation. The following 
management is described in Figure A10
Back to routine screening management –
repeat cytology test every 3 years for women 
aged 25-49 years and every 5 years for 
women aged 50-64 years.
Borderline/ mild 
dyskaryosis Colposcopy evaluation. The following 
management is described in Figure A9
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Figure A8.  Follow-up management for women referred to colposcopy, found to have confirmed CIN1 and not treated 
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Negative
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management: 
cytology test
Return to routine screening 
management described in 
Figure A7
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dyskaryosis
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dyskaryosis or 
worse
Negative
Borderline/ mild 
dyskaryosis
Repeat cytology test in 12 months. 
Managed as per ‘Annual follow-up 
management’ described in this 
figure. Women tested negative in 2 
consecutive 12-months follow-up 
will return to routine screening 
management described in Figure A7
With recent moderate 
dyskaryosis or worse result 
in the last 12 months
Without recent moderate 
dyskaryosis or worse result 
in the last 12 months
Colposcopy evaluation. The 
following management is 
described in Figure A10
Colposcopy evaluation. The 
following management is 
described in Figure A9
Colposcopy evaluation. 
The following 
management is 
described in Figure 
A10
Colposcopy evaluation. The 
following management is described 
in Figure A10
Colposcopy evaluation. The 
following management is described 
in Figure A9
Annual follow-up 
management: cytology 
test
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4.7 Routine post-colposcopy management 
Routine post-colposcopy management is depicted in Figures A9 and A10. The structures were 
constructed according to the recommendations of the 2004 NHS guidelines.10  Women referred with 
borderline or mild dyskaryosis who had satisfactory and normal colposcopy were followed at 6-
months and were managed as shown in Figure A8. Women with satisfactory and abnormal 
colposcopy were further diagnosed with punch biopsy. Women diagnosed with invasive cervical 
cancer were referred to cancer treatment. Women with histologically-confirmed CIN2/3 were treated, 
as were 7% of women with histologically-confirmed CIN1 (consistent with observed data on women 
with confirmed CIN1 from the Sentinel Sites).9  All women treated for CIN were followed at 6 
months post-treatment, and managed according Figures A2, A3 and A4.  The remaining women with 
histologically-confirmed CIN1 and all women with negative histology were referred to repeat cervical 
screening in 6 months and were managed as shown in Figure A8. Women with unsatisfactory 
colposcopy findings were managed as per women with satisfactory and normal colposcopy if they 
were aged less than 50 years; women aged 50 years or over were treated with cone biopsy. Among 
women who received cone biopsy treatment, women diagnosed with cancer were referred to cancer 
treatment; women diagnosed with histologically-confirmed CIN were referred to post-treatment 
follow-up in 6 months (described in Figures A2, A3 and A4); and women with negative histology 
were followed at 6 months follow-up as per women with satisfactory and normal colposcopy result. 
 
Women referred with moderate or severe dyskaryosis with a subsequent satisfactory but abnormal 
colposcopy were further diagnosed with punch biopsy; those with a satisfactory and normal 
colposcopy result or with unsatisfactory colposcopy findings were treated with cone biopsy, although 
women aged less than 50 years with unsatisfactory colposcopy findings were assumed to have the 
treatment delayed for 12 months.  
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Figure A9. Colposcopy management for women with borderline/mild cytology referral 
 
* Depending on which management protocol is being modelled; see Figure A2 for cytological only follow-up; A3 for Sentinel Sites protocol; A4 for Extended 
Follow-up Protocol) 
Satisfactory 
result
Unsatisfactory 
result
Abnormal
Cancer
Histologically-
confirmed CIN 2/3
Negative
Normal
Age > = 50 years
Age < 50 years
Colposcopy
Punch Biopsy
Cancer treatment
Cancer
Histologically-
confirmed CIN1
Negative
Cancer treatment
Cone Biopsy
Histologically-
confirmed CIN 1
7%
93%
Repeat cytology in 6 months. The following 
management  is described as ‘6-months 
follow-up management ’ in Figure A8
Treatment for CIN. The following 
management is described as ‘6-months post-
treatment management’ in Figure A2-A4*
Treatment for CIN. The following 
management is described as ‘6-months post-
treatment management’ in Figure A2-A4*
Repeat cytology in 6 months. The following 
management is described as ‘6-months 
follow-up management ’ in Figure A8
Repeat cytology in 6 months. The following 
management is described as ‘6-months 
follow-up management ’ in Figure A8
Repeat cytology in 6 months. The following 
management is described as ‘6-months 
follow-up management ’ in Figure A8
Post-treatment follow-up in 6 months. 
Management described as ‘6-months post-
treatment management’ in Figure A2-A4*
Repeat cytology in 6 months. The following 
management is described as ‘6-months 
follow-up management ’ in Figure A8
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Figure A10. Colposcopy management for women with moderate/severe cytology referral  
 
 
 
  
Satisfactory 
result
Unsatisfactory 
result
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Normal
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Colposcopy
Punch biopsy.  The following 
management as per management of 
punch biopsy described in Figure A9
Delay treatment for  12 months. The 
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management of cone biopsy 
described in Figure A9
Cone biopsy. The following 
management as per management of 
cone biopsy described in Figure A9
Cone biopsy. The following 
management as per management of 
cone biopsy described in Figure A9
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5. Model validation 
5.1 CIN detected at the 6 month visit 
Histological CIN status at 6 months post treatment was available from the HPV Sentinel Sites 
implementation study, and for a cohort of women treated for CIN in London, Manchester, and 
Aberdeen.11 A summary of the range of CIN detection rates seen, considering in both studies, is 
shown in Table A5. The model predictions for CIN 1 and CIN 2+ at 6 months were within this 
observed range. 
 
Table A5. Histologically detected* CIN at a follow-up visit 6 months after treatment 
Group CIN 1 CIN 2/3 
All treated women 1.4 – 2.7% 0.9 – 1.2%** 
Model prediction 2.5% 1.2% (for CIN2+) 
Source: Kitchener 200811 and data from HPV Sentinel sites (personal communication Rachel Kelly, Institute of Cancer 
Research, London UK). 
 
* Women were referred for colposcopy following a result of either cytology borderline dyskaryosis or worse, or a positive 
HPV test. 
**Based on rates of 0.4-0.6% for CIN2 and 0.5-0.6% for CIN3 
 
 
5.2  CIN detected at subsequent visits 
Histological CIN status at 12 and 24 months post-treatment was available for a cohort of women 
treated for CIN in London, Manchester, and Aberdeen,11 and at 6 years post-treatment for a cohort of 
women treated for CIN in British Columbia.14  In order to compare model predictions with the data 
from British Columbia, we assumed an age and index diagnosis distribution in the treated cohort 
consistent with the primary analysis population (see Table A3), and restricted the comparison to 
exclude women treated with cryotherapy. Model predictions were consistent with these findings 
(Table A6).   
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Table A6. Histologically detected CIN 2+ at follow-up visits 12 and 24 months after treatment 
Cumulative % with CIN2+ by:  Model prediction Target Source 
12 months 1.3 – 1.7%* 1.7% 11 
24 months 1.8 - 2.8%* 2.5% 11 
6 years    
For treatment with LEEP only 7.9% 7.5% (95% CI: 6.6 – 8.3%) 14 
Average for treatment with cone, 
LEEP, and laser 
7.8% 14 
* A range is presented based on varying compliance assumptions 
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